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A B S T R A C T
Malignant pleural mesothelioma (MPM) is a rare cancer originated from pleural mesothelial cells. MPM
has been associated with long-term exposure to asbestos. In this work we performed a comparative
proteomic analysis of biphasic pleural mesothelioma (B-PM).
Tissue biopsies were obtained from 61 patients who were subjected to a diagnostic thoracoscopy. 2D/
MS based approach was used for proteomic analysis. The 22 proteins found differentially expressed in B-
PM, with respect to benign, were analyzed by Ingenuity Pathways Analysis and compared with those
obtained for epitheliod pleural mesothelioma (E-PM). A different activation of transcription factors,
proteins and cytokines were observed between two subtypes.
ã 2016 The Authors. Published by Elsevier B.V. on behalf of European Proteomics Association (EuPA). This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Malignant pleural mesothelioma (MPM) is an asbestos-
induced, aggressive tumour, showing resistance to chemo- and
radio-therapy and very poor outcome [1,2]. From a cytomorpho-
logic point of view MPM can be distinguished in three different
categories including epithelioid, biphasic and sarcomatoid. Bi-
phasic tumours are characterized by the concomitant presence of
epithelioid and sarcomatoid cells in close proximity or, more
frequently, within distinctly separate areas of a tumour [3]. The
response of biphasic tumour to treatment depends on the ratio of
these two cellular subtypes. A tumour with the prevalence of
sarcomatoid cells is associated with worse prognosis. Although a
lot of efforts have been underway, aiming to identify the potential
targets for novel therapies, no progress has been made in
prolonging the median survival of 1 year from the time of
diagnosis [4–6]. MPM is highly resistant to therapy, therefore
surgery associated with treatments as radiotherapy and* Corresponding author at: Department of Pharmacy, University of Pisa, Via
Bonanno, 6, 56126 Pisa.
E-mail address: antonio.lucacchini@farm.unipi.it (A. Lucacchini).
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).chemotherapy are preferred [7]. So, it is urgent to advance in
our knowledge about the disease pathogenesis and to develop
more effective therapies for different subtype of mesothelioma.
Our group has recently performed a comparative proteome
analysis between epithelioid mesothelioma (E-PM) and hyperpla-
sia tissue biopsies. We showed that E-PM samples evidenced an
altered expression of nuclear lamin and ﬁlament related proteins,
in addition to conﬁrming the validity of calretinin as a potential
biomarker in the differential diagnosis of MPM [8]. In the present
study we extended the comparative proteomic analysis to the
biphasic mesothelioma (B-PM) searching for proteins that may
play a role in the transition from epithelioid to the most aggressive
biphasic phenotype.
2. Materials and methods
2.1. Materials
IPG strips pH 3–10 NL and dry strip cover ﬂuid were purchased
from GE Health Care Europe (Uppsala, Sweden). The ECL detection
system was purchased from PerkinElmer (MA, USA). Anti-S100A11
(calgizzarin), anti-serum amyloid A1(SAA1) and anti-chloride
intracellular channel protein 3 (CLIC3) speciﬁc primary antibodiesics Association (EuPA). This is an open access article under the CC BY-NC-ND license
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from Cell Signaling Technology (MA, USA). Goat anti-rabbit
IgG-HRP conjugate secondary antibody was from stress gene. All
other reagents were acquired from standard commercial sources
and were of the highest grade available.
2.2. Patients
Sixty-one patients were enrolled at the time of diagnosis before
beginning any therapeutic treatment. Tissue biopsies were
obtained from patients who were subjected to a diagnostic
thoracoscopy. After histological examination, 23 samples were
classiﬁed as E-PM, 10 samples as B-PM, 14 samples as benign
(seven pleural inﬂammation and seven hyperplasia), and 14 sam-
ples as lung carcinoma (nine adenocarcinoma and ﬁve squamous
cells carcinoma). Benign samples were used as negative control,
while lung carcinoma samples were used in the validation step as
positive control. Each sample was coded directly at the moment of
collection, in order to avoid any personal identiﬁcation. Table 1
shows the clinical characteristics of patients.
2.3. Ethics statements
The study methodologies were conformed to the standards set
by the Declaration of Helsinki and were approved by the Local
Ethics Committee and signed consent forms were obtained from all
patients.
2.4. Protein preparation from biopsies
Proteins were precipitated from the phenol-ethanol superna-
tant obtained after treatment with TRIzol1 reagent (Life technol-
ogies, UK), the resulting pellets were resuspended in rehydration
solution (7 M Urea, 2 M thiourea, 4% CHAPS, 60 mM DTT, 0.002%
bromophenol blue) and incubated for 30 min at room temperature.
After incubation, the samples were centrifuged for 10 min at
14,000  g to remove undissolved material. Protein concentrations
were measured with a RC-DC protein assay from Bio-Rad, using
bovine serum albumin as standard. All samples were stored at
80 C until analysis.
2.5. 2D gel electrophoresis
According to histological analysis B-PM, E-PM and benign
samples were used to constitute respectively three different pools
for 2D analysis. IEF was carried out by using 18 cm Immobiline
Dry-Strips (GE Healthcare) with a nonlinear, pH 3–10, gradient.
Two-hundred micrograms of proteins were ﬁlled to 400 mL with
rehydration buffer supplemented with 1.2% v/v IPG Buffer,
pH 3–10 NL (GE Healthcare). IEF was performed at 16 C on an
Ettan IPGphor II apparatus (GE Healthcare) according to the
previously described schedule [9]. After IEF, the strips were
equilibrated as described, and SDS-PAGE was performed using the
PROTEAN-II Multi Cell system (Bio-Rad) [10]. The gels were
performed in triplicate.
2.6. Staining and image analysis
The gels were stained with Ruthenium II tris (bathophenan-
throline disulfonate) tetrasodium salt (SunaTech Inc.) essentially
as described by Aude-Garcia et al [11] with minor modiﬁcations
[8,10].The acquisition on ﬂuorescence of all gel images was
performed by “ImageQuant LAS4010” (GE Healthcare). The images
were analyzed with the SameSpots (version 4.1.3978., TotalLab,
Ltd., UK) software as previously described [12]. The protein spotswith a 2 fold of spot quantity change, p < 0.05 and q-
value < 0.05 were selected and identiﬁed.
2.7. MS analysis and protein identiﬁcation
Spots of interest were cut out from gel reference and the nano-
LC-ESI-MS/MS analysis by LTQ-Orbitrap Velos was performed as
previously described [10,12] Peak lists were generated from raw
orbitrap data using the embedded software from the instrument
vendor (extract_MSN.exe). The monoisotopic masses of the
selected precursor ions were corrected using an inhouse written
Perl script [13]. The peak list ﬁles were searched against the
SwissProt/trEMBL database (Release 2013 03 of 06 March 2013)
using Mascot (Matrix Sciences, London, UK). Human taxonomy (98
529 sequences) was speciﬁed for database searching. The parent
ion tolerance was set at 10 ppm. Oxidation of methionine was
speciﬁed in Mascot as a variable modiﬁcation. Trypsin was selected
as the enzyme, with one potential missed cleavage, and the normal
cleavage mode was used. The mascot search was validated using
Scaffold 4.4.5 (Proteome Software, Portland, OR). Only proteins
matching with two different peptides with a minimum probability
score of 95% were considered to be identiﬁed. The FDR at protein
and peptide level was 0.0% and 0.2% respectively (Prophet). The
reference limit to p < 0.05 for the probabilistic scores of MS/MS
assignment was 45. When multiple proteins were identiﬁed in a
single spot, the proteins with the highest number of peptides were
considered as those corresponding to the spot.
2.8. Western blot analysis
For 1D western blot (WB), all samples were processed to
validate different protein expressions found with 2D analysis.
Aliquots (25 mg of proteins) of each sample (23 E-PM, 10 B-PM,
14 benign, and 14 lung carcinoma) were solubilized with a SDS
sample buffer (Laemmli solution), and proteins were separated by
12% SDS-PAGE under reducing conditions and WB was carried out
as previously described [14]. Before blocking the nitrocellulose,
membranes were reversibly stained with 1 mM RuBP as previously
described [10]. Speciﬁc primary antibodies were diluted in
blocking buffer as follows: 1:2000 for anti-S100A11, anti-CLIC3,
and anti-SSA1 and 1:500 anti-g-enolase. The immunocomplexes
were detected using a peroxidase labeled secondary antibody (goat
anti-rabbit, 1:10000 dilution). Immunoblots were developed using
the ECL detection system. The chemiluminescent images were
acquired by LAS4010 (GE Healthcare). The experiments were
performed in duplicate. Normalization was performed on total
proteins loaded for each sample.
2.9. Statistical analysis
Statistical analysis of the three classes (B-PM, E-PM, and
benign) of gels was performed by Same Spot (TotalLab, Ltd., UK).
The software included the following statistical analysis calcula-
tions: Anova p-value, and false discovery rate (q-values). The OD of
the proteins was expressed as a percentage of the volume
(mean  SEM). For the comparison of protein expression levels
between different subtype of MPM and with respect to control
samples (benign and carcinoma samples), the antigen-speciﬁc
bands were quantiﬁed using the Image Quant-L (GE Healthcare).
The signiﬁcance of the differences (p-value  0.05) was calculated
by the Mann–Whitney test.
2.10. Signaling pathway analysis
Proteins differentially expressed, were functionally analyzed
through the use of QIAGEN’s Ingenuity Pathway Analysis (IPA,
Table 1
Clinical data of all cases included in the study.
MPM BPM Negative control Positive control
Number 23 10 14 14
Gender (%) Male 20 (87) 9 (90) 9 (64) 7 (50)
Female 3 (13) 1 (10) 5 (36) 7 (50)
Age Mean 62.8 66.5 63 67
Range 35–80 47–83 55–82 57–81
Smoke (%) 5 (22) 2 (20) 2 (14) 6 (43)
Asbestos exposure (%) 16 (70) 6 (60) 5 (36) 7 (50)
Stage I NA NA NA 3 (21)
II 18 (78) 3 (30) NA 8 (57)
III 5 (22) 7 (70) NA 2 (14)
IV NA NA NA 1 (7)
Mesothelioma histology (%) Epithelial 23 (100) NA NA NA
Biphasic NA 10 (100) NA NA
Cancer histology (%) Squamous cell carcinoma NA NA NA 6 (43)
Adenocarcinoma NA NA NA 8 (57)
Benign histology (%) Pleural inﬂammation NA NA 7 (50) NA
Hyperplasia NA NA 7 (50) NA
NA: not applicable.
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aim to determine the predominant canonical pathways and
interaction network involved. Swiss-Prot accession numbers and
ofﬁcial gene symbols were inserted into the software along with
corresponding comparison ratios. Using the direction of change of
the proteins in our data set, the downstream effects analysis was
performed and the likely effect on disease and cell biological
processes was evaluated. Moreover, a comparison of the analysis
obtained by the proteomic proﬁles of B-PM and E-PM with respect
to benign, was created and the upstream regulators whose activity
appears to change in signiﬁcantly manner according to the
activation z-score value, were showed.Fig. 1. (A) Representative 2D gel map of B-PM. Spots circled indicate all the proteins id
Histograms of the normalized OD density volumes (mean SEM) of the protein spots fou
are based on ANOVA; B-PM vs benign (*p < 0.05, **p < 0.01, ***p < 0.001); B-PM vs E-PM3. Results
3.1. Comparative proteomic analysis of MPM subtype biopsies
A differential analysis among B-PM, E-PM and benign was
performed using 2DE followed by nano-LC-ESI-MS/MS. A repre-
sentative image of B-PM samples is shown in Fig. 1A. After
computational comparison of images obtained by different classes
(B-PM, E-PM and benign), 26 protein spots were found to be
differentially expressed with 2 fold change of mean value spot
intensities in the B-PM with the respect to benign samples. These
protein spots collapsed into the identiﬁcation of 22 differententiﬁed by nano-LC-ESI MS/MS and the spot numbers are reported in Table 1. (B)
nd in signiﬁcantly different quantities from the comparisons. Signiﬁcant differences
 (#p < 0.05, ##p < 0.01, ###p < 0.001).
Table 2
MS/MS data of protein spots differentially expressed, together with statistical analysis.
# ProteinName ID
MW pI Mat ch
pep.
Cov 
(%)
 Best Ion 
Score
BPM /benign B-PM/E-PM E-PM/benign
th obs th obs FV p-value FV p-value FV p-value
818 Alpha-enolase P06733 47 53 7.0 6.8 6 20 82.2 2 0.0194 1.3 0.0162 1.6 ns
942 Keratin, type II  cytoskeletal 7 P08729 51 49 5.4 5.3 13 34 80 .8 3 0.0007 1.2 ns 3.7 0.0004
1033 Doli chyl-diphosphooli gosac charide--protein glycosylt ransferase 48 kDa subun it P39656 51 45 6.1 5.6 3 8 78 .9 2 0.0038 2.6 0.0001 1.3 ns
1044 Alpha-enolase P06733 47 44 7.0 6.3 12 39 102 .6 2.1 0.0125 1.3 ns 1.5 ns
1048 Gamma-enolase P09104 47 44 4.9 4.8 3 9 74 .8 12 .2 0.0007 6 0.000 02 2 ns
1049 Rab GD P diss ociati on inhibit or beta P50395 51 44 5.0 5.9 7 16 74 .1 2.3 0.0074 2 0.0157 1.2 ns
1050 Rab GD P diss ociati on inhibit or beta P50395 51 44 5.0 6.1 15 36 80 .2 2 0.0050 1.4 ns 1.4 ns
1071 Alpha-centractin P61163 43 43 6.2 6.3 7 28 121 .9 2.2 0.0119 1.7 0.0180 1.3 ns
1139 Septin-2 Q15019 41 41 6.1 6.2 6 30 103 .9 2.6 0.0013 1.5 0.0373 1.7 ns
1166 Acti n-related protein 2 P61160 45 41 6.3 6.3 4 14 71 .4 2.7 0.0060 2.1 0.0077 1.3 ns
1187 Fibrinogen beta chain P02675 56 40 8.5 5.5 6 19 109 4.4 0.0003 2.5 0.0021 1.8 0.0001
1426 Annexin A8-li ke protein 2 Q5VT79 37 34 5.4 5.5 11 45 116 .1 2.3 0.0010 1.9 0.0062 4.3 0.0001
1490 Annexin A4 P09525 36 33 5.8 5.6 6 19 91 .3 2.2 0.0001 1.1 0.0177 2.4 0.0001
1531 Proteasome subunit alpha type -1 P25786 30 32 6.1 6.2 4 24 60 .7 2 0.0450 1.2 ns 1.7 ns
1610 Carbonic anhydr ase 1 P00915 29 30 6.6 6.6 8 43 99 .9 1.8 0.0011 3.2 0.0015 1.7 0.028
1614 Chloride intracell ular channel protein 3 O95833 27 30 5.9 6.0 3 20 72 2.4 0.0069 1.3 ns 1.9 ns
1629 Carbonic anhydr ase 1 P00915 29 29 6.6 6.2 3 12 71 .4 2.3 0.0049 3.2 0.0001 1.4 ns
1750 Apoli poprotein A-I P02647 31 27 5.6 5.1 2 8 74 .6 3.7 0.0229 3.9 0.0001 1.1 ns
1816 Glutathione S-transferase P P09211 23 26 5.4 5.5 5 34 147 .6 2.1 0.0002 1 ns 2.0 0.0002
2001 Peroxiredoxin-2 P32119 22 23 5.7 5.5 7 30 99 .5 1.7 0.0004 2.4 0.000 01 1.4 0.001
2185 Alpha-crystall in B chain P02511 20 21 6.7 6.9 4 35 65 .2 5.9 3,6E -07 1.1 ns 6.7 0.0003
2766 Serum amyloid A-1 protein P0DJI8 14 14 6.3 6.0 3 38 83 .0 9 0.0002 5 0.0008 1.8 ns
2783 Peroxiredoxin-1 Q06830 22 14 8.3 5.6 2 11 45 5.7 0.000 01 7.1 0.0001 1.2 ns
2846 Protein S100-A11 P31949 12 12 6.6 5.9 4 31 59 .2 2.7 0.0005 3.2 0.0023 1.2 ns
3186 Serum amyloid P-component P02743 25 29 6.1 5.5 5 26 105 .8 2.5 0.0002 2.7 0.000 03 1.1 ns
3197 Alpha-enolase P06733 47 44 7.0 6.6 15 44 112 .2 2.2 0.0190 1.7 0.0358 1.3 ns
The highlighted proteins concur at a net separation between BPM and other classes, after PCA analysis.
FV, fold variation; ns, not signiﬁcant.
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weight (MW), pI, score, and coverage values of MS/MS, the fold
change in protein expression and their relative p values obtained
from the selected comparisons (B-PM vs benign and vs E-PM). Rab
GDP dissociation inhibitor b, a-enolase (ENO1) and carbonic
anydrase I were present with more spots with different observed
MW and/or pI suggesting the existence of protein isoforms or post-
translational modiﬁcations. PCA analysis was performed by
SameSpot (data not shown) and the proteins which concur at a
net separation between BPM and other classes, are highlighted in
Table 2. Fig. 1B shows the histogram of the proteins found
differentially expressed in B-PM with respect to other classes.
3.2. Validation of B-PM proteins by WB analysis
According to PCA analysis, among proteins that resulted
discriminating for MPM subtypes, we selected SAA1, S100A11,
g-enolase and CLIC-3. The validation of the different protein
expression, obtained by immunoblot analysis, conﬁrmed the
different expression of all ﬁve proteins in B-PM with respect to
the cognate E-PM subtype. Representative western blot are shown
in Fig. 2. For each tested protein the OD of speciﬁc immunoreactive
band was determined and the resulting mean values  SEM were
compared (B-PM vs benign, B-PM vs E-PM, BPM vs carcinoma). As
shown in Fig. 2, it is conﬁrmed signiﬁcant the increase of
expression only for SAA1 (p-value = 0.033) and g-enolase (p-
value = 0.042) in B-PM with respect to E-PM. A signiﬁcant
difference was also observed with respect the positive and
negative controls (p < 0.05) for all four proteins.3.3. IPA analysis
All the proteins derived from the proteomic comparison of
B-PM vs benign were included in bioinformatic analysis to identify
molecular and cellular functions and to investigate whether these
proteins work together in speciﬁc networks. Moreover, all the
proteins found up- and down-regulated may concur both in a
downstream effects analysis and an upstream regulator analysis to
predict if diseases/biological processes and transcription factors or
genes could be activated or inactivated in agreement with z-score
value (z-score > 2, and p < 0.05), respectively. Fig. 3A shows the
downstream effects analysis. A signiﬁcant decrease of activation
state of synthesis of reactive oxygen species, respiratory system
tumor and cell death with z-scores of 2.6, 2.2 and
2.2 respectively, was predicted. At the same time a signiﬁcant
increase (p = 0.0023) of activation of phagocytes was observed
with z-score = 2. Finally, the canonical pathways coupled to
downstream effects were showed. In addition, Fig. 3B shows the
heat map generated by the comparison of IPA analysis (B-PM vs
benign and E-PM vs benign) and displays the molecules predicted
activated (red) or inactivated (green) in the two different MPM
subtypes.
4. Discussion
MPM is a lethal asbestos-associate cancer with poor respon-
siveness to current chemotherapeutic drugs, which is often
correlate to its high resistance to apoptosis [7,15]. This is
particularly true for the biphasic, an aggressive MPM subtype. In
Fig. 2. Validation of SAA1 (A), CLIC3 (B), ENO2 (C), S100-A11 (D) by WB. The bar graph shows the mean  SEM of the normalized OD values. The staining by rutenium was used
as a protein-loading control. Statistical signiﬁcance of the differences was calculated by Mann–Whitney (*p < 0.05, **p < 0.01 ***p < 0.001).
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ESI/MS/MS spectrometry techniques, we performed a comparative
analysis of proteomes of E-PM and benign biopsies’ proteic extracts
evidencing an altered expression of nuclear lamin and ﬁlament-
related proteins [8]. In this work we extended the comparative
proteomic analysis to the B-PM characterized by a combination of
elements of epitheliod and sarcomatoid subtypes. Comparative
analysis of each MPM subtype with benign deﬁned a panel of
22 proteins that showed signiﬁcant values of increase in B-PM but
not in E-PM, exception for Keratin type II cytoskeletal 7 (KRT7),
Annexin A8-like protein 2 (ANXAA8L2), Annexin A4 (ANXAA4),
Carbonic anydrase I (CA1), Glutatione S-transferase P (GSTP1),
Peroxiredoxin 2 (PRDX2) and Alpha-crystallin B chain (CRYAB),
suggesting a peculiar biphasic protein proﬁle. Moreover, 13 pro-
teins showed to discriminate B-PM with high fold changes. By
western blot analysis, the differences of expression were con-
ﬁrmed for 4 proteins (g-enolase, SAA1, protein S100A11, CLIC3) but
the capability to differentiate B-PM from E-PM was conﬁrmed for
g-enolase and SAA1, not for S100A11 and CLIC3.In vertebrate organisms three isoenzymes of enolase, expressed
by different genes, are present: a-enolase (ENO1) is ubiquitous;
b-enolase (ENO3) is muscle-speciﬁc and g-enolase (ENO2) is
neuron-speciﬁc [16]. In B-PM samples we found a signiﬁcant
increase of two isoforms of enolase, the ENO1 and the ENO2. The
latter appears to give the higher difference of expression in B-PM
when compared with benign samples, as conﬁrmed also by
western blot analysis. ENO2 has been suggested as a tumour
marker and it is used in diagnosis and prognosis of cancer;
however, the mechanisms enrolling it in malignant progression
remain elusive [16,17]. ENO2 might therefore have a multifunc-
tional role in cancer progression: as glycolytic enzyme it
participates to accelerate the glycolysis, which supports increased
tumour cells metabolic demands and enables their proliferation
[18]. An additional role of ENO2 in cancer progression is its
involvement in actin remodeling and consequently in promotion of
migration and invasion of tumour cells [17]. Finally, noteworthy,
the role of ENO2, suggested by Soh et al. [19] in breast epithelial cell
and urothelial cell cancers, provides evidence that environmental
Fig. 3. (A) Analysis of downstream effects coupled to the most signiﬁcantly affected canonical pathways and diseases/functions in BPM. (B) Heat map showing the activated
(red) or inactivated (green) predicted molecules in two different conditions: B-PM and E-PM. The brighter the color, the more intense the change will be.
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changes in epigenetic regulation of genes, which speciﬁcally affect
the expression and function of ENO2. In our view, the expression of
different isoforms of this enzyme could be correlated to different
features of MPM subtypes. Indeed, we previously showed a
reduction of ENO3 in E-PM [8] but not difference of expression of
other two isoforms was observed.A very intriguing matter is the peculiar and high increase
observed for SAA1 and SAP belonged to the acute phase proteins,
that are produced in response to infections and also to some non
infectious insults [20]. In the contest of inﬂammation, SAA1 has
been described to induce cytokines expression [21]. to modulate
cell adhesion and migration [22] and to binding laminin [23]. In
neoplastic diseases, SAA1 induces the increase of expression of
48 L. Giusti et al. / EuPA Open Proteomics 10 (2016) 42–49MMP2 and MMP9 leading to an excess of degrading activity that is
supposed to be linked to the invasive character of tumour cells
[24,25]. On the other hand, in the lung, SAA1 should not be
considered alone as a speciﬁc biomarker of lung cancer since its
increase is high also in the smokers [26]. SAP is a member of
pentraxin family and presents a 66% of homology with C-reactive
protein [27,28]. In humans, the levels of SAP in the plasma are
relatively constant. In mice, SAP acts as an acute phase protein,
with levels rising up following an inﬂammatory insult [29]. SAP
also inhibits ﬁbrosis, by inhibition of ﬁbrocyte differentiation and
regulating macrophage polarization [30]. Moreover, SAP induces
the production of anti-inﬂammatory cytokines such as IL-10 and
IL-6, inhibits pro-ﬁbrotic M2a macrophages, and promotes the
formation of immuno-regulatory Mreg macrophages [27]. In our
context we could speculate that the increase of SAP might be a
protective response to the injury induced by asbestos ﬁbers.
Among the validated proteins, the increase of CLIC3 values was
found in all types of cancer. CLIC3, together with CLIC4, was found
to be overexpressed in MPM by Tasiopoulou et al. [31] who
suggested that these proteins play a role in the transition from an
epithelioid to a sarcomatoid phenotype. The trend to increase, that
we highlighted in our samples, could be in agreement with this
hypothesis.
Nonetheless, we believe that the difference in expression of the
proteins found in B-PM subtype can help us to explore in deep the
potential pathways and molecules (e.g. transcription factors) that
could play a role in the differentiation of main features of two MPM
hystotypes. Thus, we performed IPA analysis of 22 proteins found
differentially expressed in B-PM with respect to benign samples
and we compared it with that previously obtained for E-PM.
Intriguingly, heat map shows a very different proﬁle of activation.
In fact, the nuclear factor erythroid 2-related factor 2 (NFE2L2 or
Nrf2), the cytokine IL-6 and the tumour suppressor TP53 were
signiﬁcantly activated in B-PM, while were turned off in E-PM. On
the other hand, prolactin (PRL) and N-myc proto-oncogene protein
(MYCN) resulted activated and inhibited respectively, in E-PM.
Nrf2 is a redox-sensitive transcription factor that controls the
transcription of genes encoding various antioxidative and cyto-
protective proteins [32]. Upon exposure to oxidants, Kelch-like
ECH-associated protein (Keap1), a cytosolic repressor protein that
binds to Nrf2, is inactivated. This event results in dissociation of
Nrf2-Keap1 complex, with the consequent translocation of Nrf2 to
the nucleus, where it induces the transcription and protein
synthesis of detoxifying enzymes (as glutathione-S-transferase,
GSTP1), antioxidant enzymes and proteins (as peroxiredoxin 1,
PRDX1) [32]. In our IPA analysis the target molecules in dataset,
which predicted the upstream Nrf2 activation, were SAP, SAA1,
GSTP1, PRDX1 and proteasome subunit a-type 1 (PSMA1). The
protective effect from oxidative insults, employed by products of
Nrf2 activation, is responsible to attenuate efﬁcacy of anticancer
drugs by scavenging ROS, and enhance drug resistance. With
respect to this point, and in agreement with our evidences, Lee
et al. [33] demonstrated the importance of Nrf2 in cytoprotection,
survival, and drug resistance on MSTO-211H, a biphasic cell line,
suggesting the targeting of Nrf2 as a promising strategy for
overcoming resistance to chemotherapeutics in MPM. As far as
the IL-6 concerned, its role as mediator of pivotal processes is
emerging, such as proliferation and chemoresistance within the
mesothelioma microenvironment [34]. Although elevated serum
concentration of IL-6 has been implicated as a poor prognostic
factor in some advanced carcinomas, not yet a role in MPM has
been established. However, there are evidences associating IL-
6 with established poor prognostic factors of MPM, including
trombocytosis and elevated protein reactive C (CRP) [35]. Similarly,
our results suggest an upstream activation of Il-6 predicted byelevated levels of proteins of acute response such as SAP and SAA1,
in addition to ENO2 and apolipoprotein 1 (APO1).
In conclusion, among all solid cancers, MPM is surely
considered as one of the worse diseases in terms of its inherent
chemoresistance, resulting in poor survival rates and disappoint-
ing responses to novel agents which have showed a promising
activity in other tumours. In light of these facts, there is an obvious
need to look for new therapeutic targets, together with the
research of molecules, upstream regulators, and pathways
involved in the different grade of malignancies and aggressiveness.
Overall, our results conﬁrm similarity and suggest divergence
between two MPM subtypes. Their origin could be a different
response of cells to the same detrimental agent (asbestos), which is
achieved with a different activation or inhibition of transcription
factors, obtaining different grade of malignancies.
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